Program
Enoxaparin
Also written as “Enoxaparin sodium”, “Enoxaparine” and “enoxaparin”.
Its studies are mostly in Venous Thromboembolism · Venous Thrombosis · Myocardial Infarction · Thromboembolism · Acute Coronary Syndrome, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 130 open or running | phase 4since Feb 12, 2004 | Aug 13, 2002 | none ahead |
| Les Laboratoires des Médicaments Stériles | 40 open or running | phase 4since May 14, 2011 | May 14, 2011 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 3since Jul 2, 2014 | Jul 2, 2014 | none ahead |
| Chemi | 20 open or running | phase 1since Mar 6, 2014 | Mar 6, 2014 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 3since Jan 17, 2007 | Jan 17, 2007 | none ahead |
| Egyptian International Pharmaceutical Industries | 11 open or running | phase 1since Mar 17, 2026 | Mar 17, 2026 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since May 18, 2011 | May 18, 2011 | none ahead |
| Fertility Center of Las Vegas | 11 open or running | phase 4since Nov 10, 2023 | Nov 10, 2023 | none ahead |
| PT Bio Farma | 10 open or running | phase 4since Oct 29, 2023 | Oct 29, 2023 | none ahead |
| rovi-pharmaceuticals-laboratories | 10 open or running | phase 1since Nov 29, 2017 | Nov 29, 2017 | none ahead |
| Venus Remedies | 10 open or running | phase 1since Feb 22, 2022 | Feb 22, 2022 | none ahead |
Also a collaborator on its studies: parexel and pra-health-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Aug 13, 2002.
- Jul 24, 2008Phase 3 study in Abdominal NeoplasmsSanofi · NCT00723216 · 151 enrolled · Japan
- May 14, 2011Les Laboratoires des Médicaments Stériles's first study: phase 4 study in Venous ThrombosisNew to Les Laboratoires des Médicaments StérilesLes Laboratoires des Médicaments Stériles · NCT01354704 · 153 enrolled · Tunisia
- May 18, 2011Eurofarma Laboratorios's first study: phase 3 study in Angina, UnstableNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT01356992 · 62 enrolled · Brazil
- Sep 11, 2012Phase 4 study in Acute Coronary SyndromeLes Laboratoires des Médicaments Stériles · NCT01687491 · 179 enrolled · Tunisia
- Mar 6, 2014Chemi's first study: phase 1 study in Clexane is Administered to Healthy VolunteersNew to ChemiChemi · NCT02081950 · 14 enrolled · United Kingdom
- Jul 2, 2014Boehringer Ingelheim's first studies: 2 phase 3 studies in Myocardial InfarctionNew to Boehringer IngelheimBoehringer Ingelheim · NCT02181998, NCT02181985
- Sep 3, 2014Phase 1 study in Enoxaparin Sodium is Administered to Healthy VolunteersChemi · NCT02232802 · 47 enrolled · United Kingdom
- May 7, 2015Phase 4 study in Gastrointestinal NeoplasmsLes Laboratoires des Médicaments Stériles · NCT02444572 · 168 enrolled · Tunisia
- Nov 29, 2017rovi-pharmaceuticals-laboratories's first study: phase 1 study in HealthyNew to rovi-pharmaceuticals-laboratoriesrovi-pharmaceuticals-laboratories · NCT03363477 · 46 enrolled
- May 7, 2018Phase 4 study in Placental InsufficiencyLes Laboratoires des Médicaments Stériles · NCT03528967 · 89 enrolled · Tunisia
- Feb 22, 2022Venus Remedies's first study: phase 1 study in HealthyNew to Venus RemediesVenus Remedies · NCT05265676 · 24 enrolled · India
- Oct 29, 2023PT Bio Farma's first study: phase 4 study in Safety IssuesNew to PT Bio FarmaPT Bio Farma · NCT06114641 · 220 enrolled · Indonesia
- Nov 10, 2023Fertility Center of Las Vegas's first study: phase 4 study in Infertility, FemaleNew to Fertility Center of Las VegasFertility Center of Las Vegas · NCT06133803 · 130 planned · United States
- Mar 17, 2026Egyptian International Pharmaceutical Industries's first study: phase 1 study in Healthy Participants StudyNew to Egyptian International Pharmaceutical IndustriesEgyptian International Pharmaceutical Industries · NCT07517289 · 26 planned
TargetBeta
“Antithrombin-III activator”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07517289Healthy Participants Study | 1 | Not yet recruiting | Egyptian International Pharmaceutical Industries | Jun 2026 | 26 |
| NCT06133803Infertility, Female · United States | 4 | Recruiting | Fertility Center of Las Vegas | Dec 15, 2024 | 130 |
| NCT06114641Safety Issues · Indonesia | 4 | Completed | PT Bio Farma | Feb 5, 2024 | 220 |
| NCT05265676Healthy · India | 1 | Completed | Venus Remedies | Mar 7, 2021 | 24 |
| NCT03528967Placental Insufficiency · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | Jul 31, 2018 | 89 |
| NCT03363477Healthy | 1 | Completed | rovi-pharmaceuticals-laboratories | Dec 1, 2015 | 46 |
| NCT02444572Gastrointestinal Neoplasms · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | Jul 2020 | 168 |
| NCT02232802Enoxaparin Sodium is Administered to Healthy Volunteers · United Kingdom | 1 | Completed | Chemi | Dec 5, 2014 | 47 |
| NCT02181998Myocardial Infarction | 3 | Completed | Boehringer Ingelheim | Aug 2002 | 1,606 |
| NCT02181985Myocardial Infarction | 3 | Completed | Boehringer Ingelheim | Apr 2001 | 5,989 |
| NCT02081950Clexane is Administered to Healthy Volunteers · United Kingdom | 1 | Completed | Chemi | Mar 2014 | 14 |
| NCT01687491Acute Coronary Syndrome · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | May 2013 | 179 |
| NCT01356992Angina, Unstable · Brazil | 3 | Terminated | Eurofarma Laboratorios | Jul 2013 | 62 |
| NCT01354704Venous Thrombosis · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | Jul 2015 | 153 |
| NCT00723216Abdominal Neoplasms · Japan | 3 | Completed | Sanofi | Dec 2007 | 151 |
| NCT00685958Hip Fractures · Japan | 3 | Completed | Sanofi | Mar 2007 | 54 |
| NCT00622648Acute Illness · Brazil, China, Hong Kong and more | 4 | Completed | Sanofi | Dec 2010 | 8,329 |
| NCT00622115Thrombosis · France | 1 | Completed | Sanofi | Nov 2007 | 72 |
| NCT00423319Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Sep 2009 | 5,407 |
| NCT00349180Arthroplasty, Replacement, Hip · Japan | 3 | Completed | Sanofi | 156 | |
| NCT00347490Hemodialysis · Thailand | 4 | Completed | Sanofi | Apr 2007 | 100 |
| NCT00265993Venous Thrombosis · Turkey (Türkiye) | 4 | Completed | Sanofi | Jan 2009 | 251 |
| NCT00077844Percutaneous Coronary Intervention | 3 | Completed | Sanofi | Sep 2005 | 3,532 |
| NCT00077818Acute Coronary Syndrome | 4 | Completed | Sanofi | Feb 2005 | |
| NCT00077805Ischemic Stroke · United States, Australia, Austria and more | 4 | Completed | Sanofi | Jul 2006 | |
| NCT00077792Myocardial Infarction · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Dec 2006 | 20,506 |
| NCT00077753Venous Thromboembolism · United States, Argentina, Australia and more | 4 | Completed | Sanofi | Oct 2006 | 4,726 |
| NCT00043784Angina, Unstable · United States | 3 | Completed | Sanofi | Feb 2005 | 8,000 |
How it is read
Names in the registry
- “Enoxaparin”, 11 entries
- “Enoxaparin sodium”, 5 entries
- “Enoxaparine”, 3 entries
- “enoxaparin”, 3 entries
- “Enoxaparin Sodium”, 2 entries
Conditions, from the studies’ own filings
- Venous Thromboembolism, 4 studies
- Venous Thrombosis, 3 studies
- Myocardial Infarction, 3 studies
- Thromboembolism, 2 studies
- Acute Coronary Syndrome, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.